Regeneron Pharmaceuticals, Inc. (REGN)

1,015.67 +16.65 (+1.67%) At close: 04:00PM EDT

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13,926

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	8.18M	N/A	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	7.76M	N/A	1960
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1.68M	21.37M	1959
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply	2.01M	10.67M	1973
Mr. Christopher R. Fenimore CPA	Senior VP of Finance & CFO	N/A	N/A	1971
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer	N/A	N/A	N/A
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	N/A	N/A	N/A
Mr. Joseph J. LaRosa	Executive VP, General Counsel & Secretary	1.75M	23.23M	1959
Ms. Melissa Lozner	Senior VP & Chief Compliance Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate governance

Regeneron Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2024 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.